TCGI The Classica Group Files Patent Application for Its Method of Sterilization
Against Anthrax Bacteria Disseminated On or In Paper
Business Editors
LAKEWOOD, N.J.--(BUSINESS WIRE)--Oct. 26, 2001--The Classica
Group, Inc. (NASDAQ: TCGI) announced today that it has filed an
application with the United States Commissioner of Patents and
Trademarks for a patent for its method for sterilization against the
Bacillus anthracis disseminated in or on paper.
"We are pleased with the progress we have made in just two weeks
in developing the methodology to use our existing microwave
technology, which has been used successfully for many years in the
food industry, to combat bioterrorism," said Scott Halperin, the
Classica Group's Chairman and CEO. "While the sanification of packages
and mail is a new concept, for us it represents just one more
application of our existing system," he added.
"The testing of the system using a non-pathogenic strain of living
bacteria and spores that are the same species and close genotypically
and pheanotypically to that of Bacillus anthracis are continuing
today," said Tom Myers, Classica's Technical Director. "We will have
the results of the tests from the independent laboratory by the end of
next week and we are confident they will indicate a successful
result," he added.
The Classica Group's microwave technology segment utilizes
microwave-based technology to provide producers with the ability to
deliver food, which satisfies today's consumers' demands for bacterial
integrity, convenience in preparation, and quality. CMT's technology
kills Salmonella, E-coli, Listeria and other bacteria.
The Classica Group, Inc.'s Cucina Classica Italiana subsidiary
imports and produces under license Italian specialty cheeses and other
premium specialty foods, including the world-renowned brands from
Egidio Galbani S.p.A.
Except for historical information contained herein, the matters
discussed in this news release are forward looking statements that
involve risk and uncertainties. The forward-looking statements in this
release are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially due to a variety of factors, including without limitation
the presence of competitors with broader product lines and greater
financial resources; intellectual property rights and litigation,
needs of liquidity; and the other risks detailed from time to time in
the company's reports filed with the Securities and Exchange
Commission.
--30--mw/ny*
CONTACT: Investor Relations
Robert Koch, 877/285-5587 or 914/767-0707
info@dailyfinancial.com
KEYWORD: NEW JERSEY
INDUSTRY KEYWORD: BIOTECHNOLOGY FOODS/BEVERAGES MEDICAL
PHARMACEUTICAL PRODUCT
SOURCE: The Classica Group, Inc.
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
*** end of story *** |
